抗疟药咯萘啶与磺胺多辛及乙胺嘧啶配伍治疗恶性疟结果的分析  

ANALYSIS ON RESULTS OF ANTIMALARIAL PYRONARIDINE COMBINED WITH SULFADOXINE AND PYRIMETHAMINE TO FALCIPARUM MALARIA

作　　者：陈昌[1] 蔡贤铮[2] 车立刚[3] 陈怀录[4] 蒋妙根[5] 

机构地区：[1]中国预防医学科学院寄生虫病研究所,上海200025 [2]海南省热带病防治研究所,海口570203 [3]云南省疟疾防治研究所,思茅665000 [4]四川省寄生虫病防治研究所,成都610041 [5]浙江省卫生防疫站,杭州310009

出　　处：《实用寄生虫病杂志》1997年第3期104-107,共4页Journal of Practical Parasitic Diseases

摘　　要：本文对咯萘啶与磺胺多辛和乙胺嘧啶配伍，多年来在海南和云南的抗药性地区治疗恶性疟的结果进行综合分析，认为这种配伍不宜用于抗药性恶性疟地区的防治。因为：（1）未能明显地延缓恶性疟原虫对该种伍用产生抗药性，纵向监测于用药8年后，出现RⅢ病列，药后24h的减虫率明显下降（P＜0．05）；（2）恶性疟治疗后28d，60％左右的病例仍携带配子体，经大劣按蚊和微小按蚊血餐后，在诞腺中可查见子孢子，表明此种配伍治疗后，会引起恶性疟的传播与扩散。The peper presents a synthesis of the results for the treatment of falciparum malaria by pyronaridine combined with sulfadoxine and pyrimethamine in Hainan and Yunnan areas. for many years. It could not evidently reard the progress of resistance to the triple combination which was used on trial to treat falciparum malaria. There were about 60% of patients with gametocytes on 28th day after treatment with the combination. The sporozoites were found in the salivary gland of Anopheles dirus and An. minimus after blood meal. It showed that the triple combination in the treatment of falciparum malaria did not break down the spread and transmission of falciparum malaria.

关 键 词：咯萘啶 磺胺多辛 恶性疟 抗药性 配子体 

分 类 号：R531.305[医药卫生—内科学]